Last day of trading in BTA
In January 2018, Oncology Venture Sweden AB (”Oncology Venture”) conducted a rights issue of shares in which the public also were given the opportunity to subscribe for shares. Through the rights issue 2,745,143 shares were issued. Last day of trading in BTAs (paid subscription share) is February 21st, 2018 and stop date is February 23rd, 2018.
2,745,143 shares have been registered at the Swedish Companies Registration Office and is estimated to be distributed to each VP account/depot on February 27th, 2018. After the registration at the Swedish Companies Registration Office, the total number of shares in Oncology Venture are 13,832,716 shares. The share capital after the registration is SEK 1,936,580.24.
Sedermera Fondkommission is the financial advisor to Oncology Venture in connection with the rights issue.
For questions concerning the rights issue, please contact:
Telephone: +46 (0) 40-615 14 10
For further information, please contact
|Ulla Hald Buhl, COO andChief IR & CommunicationsMobile: +45 2170 1049E-mail: firstname.lastname@example.org||Or||Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: email@example.com|
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP® – in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates. OV-SPV 2 is a Danish company that shall test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. Oncology Venture currently holds 92 percent of the shares in 2X Oncology Inc. and 40 percent of the shares in OV-SPV 2.